O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-3.39%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$9.09B
AUM Growth
+$9.09B
(-7.8%)
Cap. Flow
+$119M
Cap. Flow
% of AUM
1.31%
Top 10 Holdings %
Top 10 Hldgs %
30.15%
Holding
185
New
27
Increased
28
Reduced
27
Closed
14
Top Buys
| 1 |
Invivyd
IVVD
|
$227M |
| 2 |
Zimmer Biomet
ZBH
|
$96.7M |
| 3 |
Biogen
BIIB
|
$47.2M |
| 4 |
HCA Healthcare
HCA
|
$47M |
| 5 |
Erasca
ERAS
|
$46M |
Top Sells
| 1 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$142M |
| 2 |
Aurinia Pharmaceuticals
AUPH
|
$78.7M |
| 3 |
Ascendis Pharma
ASND
|
$58.9M |
| 4 |
Natera
NTRA
|
$54M |
| 5 |
Elevance Health
ELV
|
$47.9M |
Sector Composition
| 1 | Healthcare | 95.45% |
| 2 | Technology | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $382M | 4.2% | 6,028,307 -15,959 | -0.3% | -$1.01M |
|
2
Prelude Therapeutics
PRLD
$68.5M
| $314M | 3.45% | 10,039,691 | – | – |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $286M | 3.14% | 2,610,355 -311,800 | -11% | -$34.2M |
|
4
Merck
MRK
$210B
| $280M | 3.08% | 3,732,400 | – | – |
|
5
Bristol-Myers Squibb
BMY
$96B
| $267M | 2.94% | 4,515,400 | – | – |
|
6
Boston Scientific
BSX
$156B
| $253M | 2.78% | 5,833,600 -1,087,000 | -16% | -$47.2M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $243M | 2.67% | 1,373,200 +109,000 | +9% | +$19.3M |
|
8
Edgewise Therapeutics
EWTX
$1.51B
| $231M | 2.54% | 13,944,680 | – | – |
|
|
9
Invivyd
IVVD
$204M
| $227M | 2.5% | +5,383,500 | New | +$227M |
|
10
PMV Pharmaceuticals
PMVP
$74.2M
| $218M | 2.4% | 7,330,423 | – | – |
|
|
11
Natera
NTRA
$23.1B
| $175M | 1.93% | 1,572,800 -485,000 | -24% | -$54M |
|
12
Iovance Biotherapeutics
IOVA
$807M
| $164M | 1.8% | 6,645,100 | – | – |
|
13
Vertex Pharmaceuticals
VRTX
$100B
| $159M | 1.75% | 877,400 -188,000 | -18% | -$34.1M |
|
|
TPTX
14
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $157M | 1.72% | 2,361,327 | – | – |
|
15
Guardant Health
GH
$8.41B
| $153M | 1.69% | 1,227,400 | – | – |
|
16
AbbVie
ABBV
$372B
| $153M | 1.68% | 1,420,600 +253,100 | +22% | +$27.3M |
|
17
UnitedHealth
UNH
$281B
| $152M | 1.67% | 389,700 | – | – |
|
18
Arcutis Biotherapeutics
ARQT
$1.86B
| $145M | 1.59% | 6,073,850 | – | – |
|
19
Intuitive Surgical
ISRG
$170B
| $139M | 1.53% | 139,600 | – | – |
|
20
SPDR S&P Biotech ETF
XBI
$5.07B
| $134M | 1.47% | 1,065,700 +130,000 | +14% | +$16.3M |
|
21
Humana
HUM
$36.5B
| $130M | 1.43% | 335,000 | – | – |
|
22
Edwards Lifesciences
EW
$47.8B
| $128M | 1.4% | 1,126,400 | – | – |
|
23
DexCom
DXCM
$29.5B
| $125M | 1.37% | 228,000 -69,400 | -23% | -$38M |
|
24
Neurocrine Biosciences
NBIX
$13.8B
| $114M | 1.26% | 1,192,015 -39,100 | -3% | -$3.75M |
|
|
GRCL
25
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $109M | 1.2% | 7,884,870 | – | – |
|